4//SEC Filing
Puissance Life Science Opportunities Fund VI 4
Accession 0001760460-20-000002
CIK 0001600132other
Filed
May 21, 8:00 PM ET
Accepted
May 22, 7:25 AM ET
Size
12.2 KB
Accession
0001760460-20-000002
Insider Transaction Report
Form 4
Puissance Capital Fund (GP) LLC
10% Owner
Transactions
- Award
Common Stock
2020-05-21$13.00/sh+1,153,846$14,999,998→ 1,153,846 total
Transactions
- Award
Common Stock
2020-05-21$13.00/sh+1,153,846$14,999,998→ 1,153,846 total
Wang Theodore T
Director10% Owner
Transactions
- Award
Common Stock
2020-05-21$13.00/sh+1,153,846$14,999,998→ 1,153,846 total
Transactions
- Award
Common Stock
2020-05-21$13.00/sh+1,153,846$14,999,998→ 1,153,846 total
Puissance Capital Management LP
10% Owner
Transactions
- Award
Common Stock
2020-05-21$13.00/sh+1,153,846$14,999,998→ 1,153,846 total
Footnotes (1)
- [F1]These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
Bellerophon Therapeutics, Inc.
CIK 0001600132
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001760460
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 7:25 AM ET
- Size
- 12.2 KB